highperformr logo

Allogene Therapeutics's Overview

Total employees275
HeadquartersSouth San Francisco
Founded2017

Allogene Therapeutics is a clinical-stage biotechnology company dedicated to pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for patients with cancer. They are focused on creating 'off-the-shelf' AlloCAR T™ products, which are designed to be readily available for a broad patient population, overcoming the logistical and manufacturing complexities of autologous CAR T therapies. Their pipeline targets various hematologic malignancies and solid tumors, leveraging advanced gene editing technologies and manufacturing processes.

Where is Allogene Therapeutics's Headquarters?

HQ Function

The headquarters serves as the central hub for corporate operations, research and development (R&D), clinical development, and strategic planning for its allogeneic cell therapy programs.

Notable Features:

The facility includes state-of-the-art research laboratories, process development labs, and office spaces designed to foster innovation in cell therapy. While a separate manufacturing facility exists, the HQ is critical for early-stage R&D and process optimization.

Work Culture:

The work culture at Allogene Therapeutics is characterized by a strong emphasis on scientific innovation, collaboration, patient focus, and a fast-paced environment typical of clinical-stage biotechnology companies aiming to bring novel therapies to market.

HQ Significance:

The South San Francisco headquarters is strategically important due to its location within a leading global biotech cluster, providing access to talent, research institutions, and a network of collaborators. It's the nerve center for advancing the company's AlloCAR T™ platform.

Values Reflected in HQ: The headquarters' focus on cutting-edge science and development infrastructure reflects Allogene's commitment to innovation, scientific excellence, and its mission to deliver transformative therapies to cancer patients.

Location:

Allogene Therapeutics's primary operations are based in the United States, with its headquarters and R&D in South San Francisco and manufacturing in Newark, CA. Its global presence is mainly characterized by the conduct of multi-center clinical trials for its AlloCAR T™ candidates, which may involve sites across North America, Europe, and potentially other regions as its programs advance. The company also engages in global collaborations for research and technology access.

Street Address:

210 East Grand Avenue

City:

South San Francisco

State/Province:

CA

Country:

USA

Allogene Therapeutics's Global Presence

Newark, California, USA

Address: Newark, California (Specific street address for manufacturing facility not broadly publicized)

Strategically located in the San Francisco Bay Area, this facility supports the company's need for scalable, in-house manufacturing capabilities, ensuring control over production and supply chain for its innovative cell therapy products.

Buying Intent Signals for Allogene Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Allogene Therapeutics

As of April 2025, Allogene Therapeutics' leadership includes:

David Chang, M.D., Ph.D. - President and Chief Executive Officer
Zachary Roberts, M.D., Ph.D. - Executive Vice President of Research & Development and Chief Medical Officer
Geoffrey Parker - Executive Vice President and Chief Financial Officer
Veer Bhavnagri - Executive Vice President, General Counsel
Che-Kai Wu, Ph.D. - Chief Technical Officer
Susie Jun, M.D., Ph.D. - Chief Development Officer
Christine Cassiano - Chief Communications Officer

Investors of Allogene Therapeutics

Allogene Therapeutics has been backed by several prominent investors over the years, including:

TPG Capital
Pfizer
Gilead Sciences
Vida Ventures
Fidelity Management & Research Company
Two River
Perceptive Advisors

Executive New Hires/Exits in the Last 12 Months

Hire2
Exits2

Over the past 12 months (May 2023 - May 2024), Allogene Therapeutics has seen key leadership changes, notably in its technical and legal departments, with new appointments to Chief Technical Officer and General Counsel, and corresponding departures.

Departures

David M. Tanen, David M. Tanen departed from his role as EVP, General Counsel.
Alison Moore, Ph.D., Alison Moore, Ph.D., departed from her role as Chief Technical Officer.

New Appointments:

Veer Bhavnagri, Veer Bhavnagri appointed as new EVP, General Counsel.
Che-Kai Wu, Ph.D., Che-Kai Wu, Ph.D., appointed as new Chief Technical Officer.
Susie Jun, M.D., Ph.D., Susie Jun, M.D., Ph.D., promoted to Chief Development Officer, taking on expanded responsibilities.

Technology (Tech Stack) used by Allogene Therapeutics

Discover the tools Allogene Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Allogene Therapeutics Email Formats and Examples

Allogene Therapeutics commonly uses the 'first.last' email format for its employees. Other potential formats could exist but this is the most frequently observed.

first.last@allogene.com

Format

jane.doe@allogene.com

Example

85%

Success rate

News and media

Allogene Therapeutics Press ReleaseMay 23, 2024

Allogene Therapeutics To Present Data from Its Phase 1 ALPHA2 Study of Cema-Cel (ALLO-501A) in Relapsed/Refractory (R/R) Large B Cell Lymphoma (LBCL) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Allogene announced it will present updated data from its Phase 1 ALPHA2 study of cema-cel (ALLO-501A) in patients with relapsed/refractory Large B Cell Lymphoma at the upcoming ASCO 2024 meeting....more

Allogene Therapeutics Press ReleaseMay 7, 2024

Allogene Reports First Quarter 2024 Financial Results and Business Update

Allogene provided an update on its pipeline progress, including its CAR T cell therapy candidates, and reported its financial results for the first quarter ending March 31, 2024....more

Allogene Therapeutics Press ReleaseApril 17, 2024

Allogene Therapeutics Announces Publication of Phase 1 ALPHA/ALPHA2 Study of ALLO-501/501A in The Lancet

Allogene announced the publication of positive data from its Phase 1 ALPHA/ALPHA2 trials of ALLO-501 and ALLO-501A in relapsed/refractory non-Hodgkin lymphoma in the peer-reviewed journal The Lancet....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Allogene Therapeutics, are just a search away.